More recently, Biogen and Eisai discontinued two phase III clinical trials (Mission AD1 and AD2, in MCI and early AD patients, respectively) with BACE inhibitor elenbecestat due to unfavorable risk-benefit ratio. This evidence concerns the gene BACE1 and Alzheimer disease.